![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Orphan Products Office to Focus on Clearing Backlog
FDA Orphan Products Office to Focus on Clearing Backlog
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
June 30, 2017
To meet its goals of clearing a backlog of about 200 orphan designation requests before Sept. 21 — and committing to 90-day reviews thereafter — the FDA has formed a “SWAT team” of reviewers dedicated to the task, starting with the oldest applications first.
The agency’s plan, released Thursday, also includes implementing a new, streamlined template for reviewing orphan designations, and a CDER-CBER pilot project to conduct preliminary evaluations in a subset of applications, with the Office of Orphan Products Development performing secondary reviews.
In addition, the plan says the FDA will “minimize discretionary work,” such as non-designation and non-grant-specific assignments and analytical work, to lighten the load for all other reviewers — as well as limiting outreach activities to projects deemed the most meaningful.
Upcoming Events
-
21Oct